PR3-ANCA test (Anti-Neutrophil Cytoplasmic Antibodies targeting Proteinase 3) is used to detect autoantibodies against the enzyme proteinase 3 in neutrophils. This test is particularly useful in the diagnosis and monitoring of Granulomatosis with Polyangiitis (GPA), formerly known as Wegener’s granulomatosis, a rare systemic vasculitis that affects small- and medium-sized vessels. PR3-ANCA, often associated with a c-ANCA pattern in immunofluorescence testing, serves as a key marker and is linked with clinical features such as inflammation of the lungs, kidneys (glomerulonephritis), sinuses, and skin. A positive result may indicate active disease or risk of relapse, and it helps guide immunosuppressive treatments (such as rituximab or cyclophosphamide).
However, PR3-ANCA can also be seen in other conditions like Microscopic Polyangiitis (MPA) or certain infections, although it is less common. Interpretation of results must be made in conjunction with clinical signs (such as pulmonary hemorrhage, nasal ulcers, or renal failure), imaging studies (such as chest CT), and tissue biopsy (to confirm granulomas). Additional tests like MPO-ANCA (associated with the p-ANCA pattern) are essential to distinguish between different types of vasculitis. A definitive diagnosis requires integrating clinical, laboratory, and pathological findings. The presence of PR3-ANCA may also help predict treatment response or identify specific disease subgroups.
